CABA Cabaletta Bio, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1759138 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-19.5%
TTM EPS YoY44.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-89.5%
ROA-72.0%
ROIC (approx.)-479.6%
Asset turnover—
Leverage & solvency
Liabilities / assets15.6%
Debt / equity0.00x
Current ratio6.55x
Interest coverage-87.26x
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $142.67M | $97.20M | $55.42M | $39.30M | $32.49M |
| SG&A expense | $29.57M | $27.94M | $19.24M | $14.84M | $13.82M |
| Operating income | -$172.24M | -$125.14M | -$74.66M | -$54.14M | -$46.31M |
| Interest expense | $2.00M | $748,000 | $0 | — | — |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$167.86M | -$115.86M | -$67.67M | -$52.98M | -$46.29M |
| EBITDA | -$170.59M | -$123.43M | -$73.23M | -$52.96M | -$45.58M |
| EPS (basic) | -2.10 | -2.34 | -1.65 | -1.81 | -1.80 |
| EPS (diluted) | -2.10 | -2.34 | -1.65 | -1.81 | -1.80 |
| Balance sheet | |||||
| Cash & equivalents | $82.98M | $163.96M | $193.24M | $81.61M | $122.22M |
| Short-term investments | $50.62M | $0 | $48.01M | $24.94M | $0 |
| Current assets | $138.87M | $166.68M | $244.49M | $108.83M | $124.54M |
| PP&E, net | $1.92M | $2.74M | $2.54M | $2.58M | $1.44M |
| Total assets | $165.08M | $185.05M | $253.65M | $116.97M | $126.34M |
| Current liabilities | $50.15M | $27.09M | $15.99M | $9.49M | $8.38M |
| Total liabilities | $53.03M | $32.71M | $17.45M | $12.45M | $8.38M |
| Shareholders' equity | $112.05M | $152.34M | $236.20M | $104.52M | $117.96M |
| Shares outstanding | 100.48M | 50.74M | 47.82M | 29.45M | 28.93M |
| Cash flow statement | |||||
| Operating cash flow | -$131.08M | -$88.22M | -$53.55M | -$46.38M | -$34.11M |
| Capital expenditure | $1.23M | $2.21M | $687,000 | $2.45M | $1.17M |
| Free cash flow | -$132.31M | -$90.43M | -$54.24M | -$48.83M | -$35.27M |
| Investing cash flow | -$50.27M | $47.29M | -$22.45M | -$27.22M | $6.00M |
| Financing cash flow | $100.35M | $11.68M | $187.63M | $32.98M | $48.90M |
| Depreciation & amortization | $1.65M | $1.71M | $1.43M | $1.18M | $733,000 |
| Stock-based compensation | $20.94M | $19.46M | $11.34M | $6.90M | $5.80M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.